Basic Information
| LncRNA/CircRNA Name | lncRNA-PRAL |
| Synonyms | PRAL, lncRNA-PRAL |
| Region | GRCh38_17:6772831-6776116 |
| Ensemble | ENSG00000279296 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Bortezomib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | multiple myeloma |
| ICD-0-3 | C42.1 |
| Methods | qPCR, Western blot, Flow cytometry, etc. |
| Sample | cell lines (NCI-H929, ARH77, PRMI8226, OPM2, JJN3) |
| Expression Pattern | down-regulated |
| Function Description | Survival curves showed that MM patients with low PRAL expression had a significantly shorter disease-free survival (DFS) and overall survival (OS) than the patients with high PRAL expression. We further identified and confirmed that miR-210 was the target of PRAL, and miR-210 overexpression overturned the potentiation effect of PRAL on BTZ efficacy. bone morphogenetic protein 2 (BMP2) was confirmed to be the target of miR-210. |
| Pubmed ID | 29944867 |
| Year | 2018 |
| Title | LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. |
External Links
| Links for lncRNA-PRAL | GenBank HGNC NONCODE |
| Links for multiple myeloma | OMIM COSMIC |